BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

15 related articles for article (PubMed ID: 38754016)

  • 1. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
    Ratnaparkhi R; Javellana M; Jewell A; Spoozak L
    Curr Treat Options Oncol; 2024 Feb; 25(2):237-260. PubMed ID: 38300479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The integration of BRCA testing into oncology clinics.
    Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S
    Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    da Cunha Colombo Bonadio RR; Fogace RN; Miranda VC; Diz MDPE
    Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e450s. PubMed ID: 30133561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M
    Gynecol Oncol; 2024 May; 187():221-226. PubMed ID: 38821039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board.
    Horn IP; Zakas AL; Smith-Simmer KJ; Birkeland LE; Sundstrom R; Burkard ME; Weiss JM
    JCO Precis Oncol; 2024 May; 8():e2300466. PubMed ID: 38810171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.
    Cheo SW; Ong PY; Ow SGW; Chan GHJ; Tan DSP; Lim YW; Kong HL; Wong ALA; Lim SE; Walsh RJ; Wong ASC; Low JJH; Ngoi NYL; Lim JSL; Lee SC
    ESMO Open; 2024 Jun; 9(6):103482. PubMed ID: 38833967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.
    Cvelbar M; Hocevar M; Novakovic S; Stegel V; Perhavec A; Krajc M
    Radiol Oncol; 2017 Jun; 51(2):187-194. PubMed ID: 28740454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Ovarian Cancer Treatment and Prevention Through Parallel Germline and Somatic Genetic Testing.
    Kwon JS
    J Natl Compr Canc Netw; 2024 Jun; 22(2D):. PubMed ID: 38862010
    [No Abstract]   [Full Text] [Related]  

  • 10. MAGENTA: a Multinational patient survey assessing the Awareness, perceptions and unmet needs in GENetic Testing and counselling among patients with breAst cancer.
    Powell S; Artigas M; Borovova I; Gadiya P; Hsu A; Kaur R; Kidd L; Rosenfeld D; Saeed MM; Scarelli E; Youssef MW
    Front Oncol; 2024; 14():1380349. PubMed ID: 38807767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL13 shapes tumor immune microenvironment in ovarian cancer with homologous recombination deficiency.
    Ding Y; Ye Z; Ding B; Feng S; Du F; Ma X; Wang X; Shen Y
    Genes Dis; 2024 Sep; 11(5):101200. PubMed ID: 38868578
    [No Abstract]   [Full Text] [Related]  

  • 12. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
    Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
    Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.